Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment (Cell Metabolism)

Best et al. identify the tumorigenic potential of Nrf2 pathway activation in lung epithelium in the context of PI3K pathway alterations. Plasma metabolite profiling suggests that tumorigenesis is associated with reprogramming of the pentose phosphate pathway. Tumor-bearing lungs exhibit an altered immune milieu and are amenable to checkpoint inhibitor therapy.